233 related articles for article (PubMed ID: 31177553)
21. Targeted next-generation sequencing using a multigene panel in myeloid neoplasms: Implementation in clinical diagnostics.
Maes B; Willemse J; Broekmans A; Smets R; Cruys B; Put N; Madoe V; Janssen M; Soepenberg O; Bries G; Vrelust I; Achten R; Van Pelt K; Buvé K; Theunissen K; Peeters V; Froyen G
Int J Lab Hematol; 2017 Dec; 39(6):604-612. PubMed ID: 28722833
[TBL] [Abstract][Full Text] [Related]
22. Feasibility and clinical utility of a pan-solid tumor targeted RNA fusion panel: A single center experience.
Hindi I; Shen G; Tan Q; Cotzia P; Snuderl M; Feng X; Jour G
Exp Mol Pathol; 2020 Jun; 114():104403. PubMed ID: 32061944
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC).
DiNardo CD; Bannon SA; Routbort M; Franklin A; Mork M; Armanios M; Mace EM; Orange JS; Jeff-Eke M; Churpek JE; Takahashi K; Jorgensen JL; Garcia-Manero G; Kornblau S; Bertuch A; Cheung H; Bhalla K; Futreal A; Godley LA; Patel KP
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):417-428.e2. PubMed ID: 27210295
[TBL] [Abstract][Full Text] [Related]
24. Applications of next-generation sequencing in hematologic malignancies.
Ramkissoon LA; Montgomery ND
Hum Immunol; 2021 Nov; 82(11):859-870. PubMed ID: 33648805
[TBL] [Abstract][Full Text] [Related]
25. Validation of CZECANCA (CZEch CAncer paNel for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromes.
Soukupova J; Zemankova P; Lhotova K; Janatova M; Borecka M; Stolarova L; Lhota F; Foretova L; Machackova E; Stranecky V; Tavandzis S; Kleiblova P; Vocka M; Hartmannova H; Hodanova K; Kmoch S; Kleibl Z
PLoS One; 2018; 13(4):e0195761. PubMed ID: 29649263
[TBL] [Abstract][Full Text] [Related]
26. Clinical Validation of FusionPlex RNA Sequencing and Its Utility in the Diagnosis and Classification of Hematologic Neoplasms.
Chen X; Wang W; Yeh J; Wu Y; Oehler VG; Naresh KN; Liu YJ
J Mol Diagn; 2023 Dec; 25(12):932-944. PubMed ID: 37813298
[TBL] [Abstract][Full Text] [Related]
27. Clinical Evaluation of Massively Parallel RNA Sequencing for Detecting Recurrent Gene Fusions in Hematologic Malignancies.
Kim B; Lee H; Shin S; Lee ST; Choi JR
J Mol Diagn; 2019 Jan; 21(1):163-170. PubMed ID: 30347268
[TBL] [Abstract][Full Text] [Related]
28. A comprehensive genomic approach for neuromuscular diseases gives a high diagnostic yield.
Ankala A; da Silva C; Gualandi F; Ferlini A; Bean LJ; Collins C; Tanner AK; Hegde MR
Ann Neurol; 2015 Feb; 77(2):206-14. PubMed ID: 25380242
[TBL] [Abstract][Full Text] [Related]
29. Clinical Utility of Implementing a Frontline NGS-Based DNA and RNA Fusion Panel Test for Patients with Suspected Myeloid Malignancies.
Bhai P; Hsia CC; Schenkel LC; Hedley BD; Levy MA; Kerkhof J; Santos S; Stuart A; Lin H; Broadbent R; Nan S; Yang P; Xenocostas A; Chin-Yee I; Sadikovic B
Mol Diagn Ther; 2022 May; 26(3):333-343. PubMed ID: 35381971
[TBL] [Abstract][Full Text] [Related]
30. An Overview of Characteristics of Clinical Next-Generation Sequencing-Based Testing for Hematologic Malignancies.
Zhang BM; Keegan A; Li P; Lindeman NI; Nagarajan R; Routbort MJ; Vasalos P; Kim AS; Merker JD
Arch Pathol Lab Med; 2021 Sep; 145(9):1110-1116. PubMed ID: 33450747
[TBL] [Abstract][Full Text] [Related]
31. Unbiased targeted next-generation sequencing molecular approach for primary immunodeficiency diseases.
Al-Mousa H; Abouelhoda M; Monies DM; Al-Tassan N; Al-Ghonaium A; Al-Saud B; Al-Dhekri H; Arnaout R; Al-Muhsen S; Ades N; Elshorbagi S; Al Gazlan S; Sheikh F; Dasouki M; El-Baik L; Elamin T; Jaber A; Kheir O; El-Kalioby M; Subhani S; Al Idrissi E; Al-Zahrani M; Alhelale M; Alnader N; Al-Otaibi A; Kattan R; Al Abdelrahman K; Al Breacan MM; Bin Humaid FS; Wakil SM; Alzayer F; Al-Dusery H; Faquih T; Al-Hissi S; Meyer BF; Hawwari A
J Allergy Clin Immunol; 2016 Jun; 137(6):1780-1787. PubMed ID: 26915675
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive evaluation and validation of targeted next-generation sequencing performance in two clinical laboratories.
Mendez P; Dang J; Kim JW; Lee S; Yoon JH; Kim T; Sailey CJ; Jablons DM; Kim IJ
Int J Oncol; 2016 Jul; 49(1):235-42. PubMed ID: 27121194
[TBL] [Abstract][Full Text] [Related]
33. Impact of next generation sequencing results on clinical management in patients with hematological disorders.
Patel BJ; Barot SV; Xie Y; Cook JR; Carraway HE; Hsi ED
Leuk Lymphoma; 2021 Jul; 62(7):1702-1710. PubMed ID: 33533694
[TBL] [Abstract][Full Text] [Related]
34. Approach Toward Germline Predisposition Syndromes in Patients with Hematologic Malignancies.
Atluri H; Gerstein YS; DiNardo CD
Curr Hematol Malig Rep; 2022 Dec; 17(6):275-285. PubMed ID: 36279069
[TBL] [Abstract][Full Text] [Related]
35. The role of molecular genetic analysis within the diagnostic haemato-oncology laboratory.
Bench AJ
Int J Lab Hematol; 2012 Feb; 34(1):21-34. PubMed ID: 21883966
[TBL] [Abstract][Full Text] [Related]
36. Concurrent detection of targeted copy number variants and mutations using a myeloid malignancy next generation sequencing panel allows comprehensive genetic analysis using a single testing strategy.
Shen W; Szankasi P; Sederberg M; Schumacher J; Frizzell KA; Gee EP; Patel JL; South ST; Xu X; Kelley TW
Br J Haematol; 2016 Apr; 173(1):49-58. PubMed ID: 26728869
[TBL] [Abstract][Full Text] [Related]
37. Current clinical practices and challenges in molecular testing: a GOAL Consortium Hematopathology Working Group report.
Lee TD; Aisner DL; David MP; Eno CC; Gagan J; Gocke CD; Guseva NV; Haley L; Jajosky AN; Jones D; Mansukhani MM; Mroz P; Murray SS; Newsom KJ; Paulson V; Roy S; Rushton C; Segal JP; Senaratne TN; Siddon AJ; Starostik P; Van Ziffle JAG; Wu D; Xian RR; Yohe S; Kim AS
Blood Adv; 2023 Aug; 7(16):4599-4607. PubMed ID: 37236162
[TBL] [Abstract][Full Text] [Related]
38. Clinical validation of targeted next-generation sequencing for inherited disorders.
Yohe S; Hauge A; Bunjer K; Kemmer T; Bower M; Schomaker M; Onsongo G; Wilson J; Erdmann J; Zhou Y; Deshpande A; Spears MD; Beckman K; Silverstein KA; Thyagarajan B
Arch Pathol Lab Med; 2015 Feb; 139(2):204-10. PubMed ID: 25611102
[TBL] [Abstract][Full Text] [Related]
39. Clinical Validation of a Myeloid Next-Generation Sequencing Panel for Single-Nucleotide Variants, Insertions/Deletions, and Fusion Genes.
Izevbaye I; Liang LY; Mather C; El-Hallani S; Maglantay R; Saini L
J Mol Diagn; 2020 Feb; 22(2):208-219. PubMed ID: 31751678
[TBL] [Abstract][Full Text] [Related]
40. Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignancies.
Mukherjee S; Sathanoori M; Ma Z; Andreatta M; Lennon PA; Wheeler SR; Prescott JL; Coldren C; Casey T; Rietz H; Fasig K; Woodford R; Hartley T; Spence D; Donnelan W; Berdeja J; Flinn I; Kozyr N; Bouzyk M; Correll M; Ho H; Kravtsov V; Tunnel D; Chandra P
Cancer Genet; 2017 Oct; 216-217():128-141. PubMed ID: 29025587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
